Results for defibrotide translation from Maltese to English

tirofiban. defibrotide.
tirofiban, defibrotide.

is-sustanza attiva hija defibrotide.
the active substance is defibrotide.

defitelio 80 mg/ml konċentrat sterili defibrotide
defitelio 80 mg/ml sterile concentrate defibrotide

ma nstabitx akkumulazzjoni ta’ defibrotide fuq 4 dożi.
accumulation of defibrotide over 4 doses was not found.

kull kunjett ta' 2.5 ml fih 200 mg defibrotide.
each 2.5 ml vial contains 200 mg defibrotide.

madankollu ebda farmakodinamika minn defibrotide ma ġiet identifikata in vivo.
however no pharmacodynamics effects from defibrotide have been identified in vivo.

defitelio 80 mg/ml konċentrat għal soluzzjoni għal infużjoni defibrotide
defitelio 80 mg/ml concentrate for solution for infusion defibrotide

defibrotide intwera wkoll li jkollu attività in vitro profibrinolitika dgħajfa.
defibrotide also has been shown to have a weak profibrinolytic activity in vitro.

ma hemm ebda studju dwar l-użu ta' defibrotide f'nisa tqal.
there are no studies using defibrotide in pregnant women.

kull kunjett ta' 2.5 ml fih 200 mg defibrotide u kull ml soluzzjoni fiha 80 mg defibrotide.
each 2.5 ml vial contains 200 mg defibrotide and each ml solution contains 80 mg defibrotide.

mhux magħruf jekk defibrotide jiġix eliminat mill-ħalib tas-sider tal-bniedem.
it is not known whether defibrotide is excreted in human milk.

sensittività eċċessiva għal defibrotide jew għal kwalunkwe wieћed mill-eċċipjenti elenkati fis- sezzjoni 6.1
hypersensitivity to defibrotide or to any of the excipients listed in section 6.1

f’sottostudju ntwera li l-emodijalisi ma neħħietx defibrotide (ara sezzjoni 4.2).
in a sub-study it was shown that haemodialysis did not remove defibrotide (see section 4.2)

għalhekk, l-użu ta' defibrotide ma' prodotti mediċinali antitrombotiċi/fibrinolitiċi mhuwiex rakkomandat.
therefore, the use of defibrotide with antithrombotic/fibrinolytic medicinal products is not recommended.

defibrotide jaħdem billi jipproteġi ċ-ċelluli tal-vażi tad-demm u jimpedixxi jew ikisser l-emboli tad- demm.
defibrotide works by protecting the cells of the blood vessels and preventing or breaking down the blood clots.

defibrotide intwera wkoll li jipproteġi ċ-ċelluli endoteljali minn apoptożi medjata bi fludarabine, filwaqt li ma għandux impatt fuq l-effett anti-lewkemiku tiegħu.
defibrotide has also been shown to protect endothelial cells from fludarabine-mediated apoptosis, while not impacting its anti-leukemic effect.

barra minn hekk, defibrotide intwera li jżid il-funzjoni tal-attivatur tal-plasminoġen tat-tip tat-tessut (t- pa) u jnaqqas l-attività tal-inibitur-1 tal-attivatur tal-plasminogen (pai-1) u dan jirriżulta fi tnaqqis fl- attività prokoagulanti u f'żieda fil-potenzjal fibrinolitika taċ-ċelloli endoteljali.
also, in vitro, defibrotide has been shown to increase tissue-type plasminogen activator (t-pa) function and decrease plasminogen activator inhibitor-1 (pai-1) activity resulting in a decrease in procoagulant activity and an increase in the fibrinolytic potential of endothelial cells.